Literature DB >> 29275824

Predictors of Survival After Treatment of Oligometastases After Esophagectomy.

Galal Ghaly1, Sebron Harrison1, Mohamed K Kamel1, Mohamed Rahouma1, Abu Nasar1, Jeffrey L Port1, Brendon M Stiles1, Nasser K Altorki2.   

Abstract

BACKGROUND: Recurrent esophageal carcinoma (EC) has a dismal prognosis. However, prior studies showed that selected patients with isolated recurrence may benefit from definitive therapy. The aim of this study was to identify the predictors of postrecurrence survival (PRS) in patients with isolated EC recurrence who were treated with curative intent.
METHODS: A retrospective review of a prospective database (1988 to 2015) was performed to identify all recurrent EC patients after curative esophagectomy. Demographic and clinicopathologic data were reviewed. The probability of PRS was estimated with the Kaplan-Meier method. Predictors of PRS after definitive therapy for isolated EC recurrence were determined by the multivariable Cox proportional hazards model.
RESULTS: Of the 640 curative esophagectomies, 241 patients (37.7%) experienced recurrences (median follow-up 50 months). Fifty-six patients (9%) received definitive treatment of isolated EC recurrence (31 were treated surgically with or without chemotherapy-radiotherapy [CTRT] and 25 received definitive CTRT alone). Median time to recurrence (TTR) was 19 months. The 1- and 3-year PRSs were 78% and 38% (median survival 26 months). On multivariable analysis; TTR was the only significant independent predictor for survival after recurrence (hazards ratio 0.98, 95% confidence interval: 0.96 to 0.99, p = 0.034). No pronounced difference was found in disease-free survival or in PRS between recurrent patients treated with operation with or without CTRT and patients who received definitive CTRT.
CONCLUSIONS: A select subgroup of patients with isolated EC recurrence can be treated with curative intent. TTR was the best predictor for PRS.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29275824     DOI: 10.1016/j.athoracsur.2017.10.039

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  9 in total

1.  Incidence and Risk Factors for Isolated Esophageal Cancer Recurrence to the Brain.

Authors:  Tamar B Nobel; Nikita Dave; Mahmoud Eljalby; Xinxin Xing; Arianna Barbetta; Meier Hsu; Kay See Tan; Yelena Janjigian; Manjit S Bains; Smita Sihag; David R Jones; Daniela Molena
Journal:  Ann Thorac Surg       Date:  2019-10-12       Impact factor: 4.330

2.  Postoperative solitary liver metastasis from esophageal squamous cell carcinoma achieving a clinical complete response to chemotherapy with cisplatin and 5-fluorouracil followed by stereotactic body radiotherapy: A case report.

Authors:  Shuichi Fukuda; Kaoru Okajima; Kaoru Okada; Kohei Fukuda; Tomoko Wakasa; Tomoyuki Tsujimoto; Atsushi Gakuhara; Hideo Tomihara; Katsuya Ohta; Kotaro Kitani; Kazuhiko Hashimoto; Hajime Ishikawa; Jin-Ichi Hida; Masao Yukawa; Yoshio Ohta; Masatoshi Inoue
Journal:  Mol Clin Oncol       Date:  2021-05-07

3.  Surveillance Implications of Recurrence Patterns in Early Node-Negative Esophageal Adenocarcinoma.

Authors:  Tamar B Nobel; Jennifer Livschitz; Xin Xin Xing; Arianna Barbetta; Meier Hsu; Kay See Tan; Smita Sihag; David R Jones; Daniela Molena
Journal:  Ann Thorac Surg       Date:  2019-07-16       Impact factor: 4.330

4.  Post-recurrence survival analysis in patients with oligo-recurrence after curative esophagectomy.

Authors:  Ping-Chung Tsai; Hung-Che Chien; Po-Kuei Hsu; Jung-Jyh Hung; Chien-Sheng Huang; Wen-Hu Hsu; Han-Shui Hsu
Journal:  BMC Cancer       Date:  2022-06-09       Impact factor: 4.638

5.  Factors Affecting the Survival of Patients with Oligometastatic Non-Small-Cell Lung Cancer: A Meta-Analysis.

Authors:  Yu Shi; Jianxin Yang; Ninghua Yao; Minghai Shao; Wenxiu Ding; Wanrong Jiang; Xinchen Sun
Journal:  Can Respir J       Date:  2019-05-19       Impact factor: 2.409

6.  Association Between Multiple Lines of Active Therapy and Prognosis in Esophageal Squamous Cell Carcinoma.

Authors:  Ying Yang; Jun Jia; Zhiwei Sun; Chuanling Liu; Yanjie Xiao; Jing Yu; Feng Du; Xiaodong Zhang
Journal:  Cancer Manag Res       Date:  2020-03-24       Impact factor: 3.989

7.  Prediction of Locoregional Recurrence-Free Survival of Oesophageal Squamous Cell Carcinoma After Chemoradiotherapy Based on an Enhanced CT-Based Radiomics Model.

Authors:  Jie Kong; Shuchai Zhu; Gaofeng Shi; Zhikun Liu; Jun Zhang; Jialiang Ren
Journal:  Front Oncol       Date:  2021-09-24       Impact factor: 6.244

8.  Predicting liver and lung metastasis in esophageal cancer: does the site of primary tumor really matter?

Authors:  Ka-On Lam; Tsz-Him So; Feng-Ming Spring Kong
Journal:  J Thorac Dis       Date:  2020-06       Impact factor: 3.005

9.  Successful multidisciplinary treatment including repeated metastasectomy for recurrent squamous cell esophageal carcinoma: a case report.

Authors:  Kosuke Hirose; Hiroshi Saeki; Yuichiro Nakashima; Tomohiro Kamori; Yoshiaki Fujimoto; Tetsuro Kawazoe; Hiroya Matsuoka; Yasuhiro Haruta; Shun Sasaki; Tomoko Jogo; Qingjiang Hu; Yasuo Tsuda; Koji Ando; Eiji Oki; Ryuzo Hiratsuka; Yoshinao Oda; Masaki Mori
Journal:  Surg Case Rep       Date:  2019-05-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.